InvestorsHub Logo
Followers 20
Posts 5396
Boards Moderated 0
Alias Born 01/04/2012

Re: None

Thursday, 02/29/2024 8:19:35 PM

Thursday, February 29, 2024 8:19:35 PM

Post# of 14991
Long- term here is another arrow in ANIP's quiver. On December 15,2023, ANIP received approval for the first generic version of AbbVie's Namzaric. Peak sale estimates are $574.1 million by 2025. AbbVie has a number of patents related to the drug with expirations ranging from 2025 to 2029. I don't know when the will be able to launch. But being first to launch with 6 months of generic exclusivity should add significantly to future revenues.

Approval

Peak sales
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News